CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/27/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 2,137 | 40.3 |
| Stockholders' equity | 3,165 | 59.7 |
| Total capitalization | 5,301 | 100.0 |
47,738,872 shares outstanding at 25 July 2026 (cover page of the 10-Q filed 5 August 2026).
LONG-TERM DEBT 12/27/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, noncurrent | 2,136 |
| Current maturities | 0 |
CAPITAL STOCK 12/27/25
| Common shares authorized | 120,000,000 |
| Common shares issued | 49,217,000 |
| Treasury shares | 0 |
| Par or stated value per share ($) | 0.01 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/25/26 | 47,738,872 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: State of incorporation not stated in SEC records. Formerly known as CHARLES RIVER LABORATORIES HOLDINGS INC (to 28 January 2000).
BUSINESS: Classified by the SEC under Standard Industrial Classification 8731, Services-Commercial Physical & Biological Research. Large accelerated filer. Principal executive office: 251 Ballardvale St, Wilmington, MA 01887. Fiscal year ends December 27. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/27/25 | 12/28/24 | 12/30/23 |
|---|---|---|---|
| Revenues | 4,015 | 4,050 | 4,129 |
| Selling, general and administrative | 743 | 751 | 748 |
| Depreciation and amortization | 403 | 362 | 314 |
| Operating income | 25 | 227 | 617 |
| Interest expense | 107 | 126 | 137 |
| Income before income taxes | (100) | 93 | 581 |
| Income taxes | 43 | 68 | 101 |
| Net income | (144) | 22 | 475 |
| Earned per share, diluted ($) | (2.91) | 0.20 | 9.22 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/27/25 | 12/28/24 |
|---|---|---|
| Cash and equivalents | 214 | 195 |
| Receivables, net | 709 | 721 |
| Inventories | 299 | 279 |
| Total current assets | 1,447 | 1,403 |
| Property, plant and equipment, net | 1,655 | 1,604 |
| Goodwill | 2,764 | 2,847 |
| Total assets | 7,135 | 7,528 |
| Total current liabilities | 1,120 | 994 |
| Long-term debt | 2,136 | 2,240 |
| Total liabilities | 3,924 | 4,020 |
| Stockholders' equity | 3,165 | 3,462 |
| Total liabilities and equity | 7,135 | 7,528 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/27/25 | 4,015 | 25 | (144) | -3.6 | (2.91) | – | 738 | 219 | 518 | 7,135 | 3,924 | 2,137 | 3,165 | -4.6 | 0.68 |
| 12/28/24 | 4,050 | 227 | 22 | 0.5 | 0.20 | – | 735 | 233 | 502 | 7,528 | 4,020 | 2,240 | 3,462 | 0.6 | 0.65 |
| 12/30/23 | 4,129 | 617 | 475 | 11.5 | 9.22 | – | 684 | 319 | 365 | 8,195 | 4,536 | 2,650 | 3,597 | 13.2 | 0.74 |
| 12/31/22 | 3,976 | 651 | 486 | 12.2 | 9.48 | – | 620 | 325 | 295 | 7,603 | 4,579 | 2,709 | 2,976 | 16.3 | 0.91 |
| 12/25/21 | 3,540 | 590 | 391 | 11.0 | 7.60 | – | 761 | 229 | 532 | 7,024 | 4,432 | 2,664 | 2,535 | 15.4 | 1.05 |
| 12/26/20 | 2,924 | 433 | 364 | 12.5 | 7.20 | – | 547 | 167 | 380 | 5,491 | 3,347 | 1,977 | 2,115 | 17.2 | 0.93 |
| 12/28/19 | 2,621 | 351 | 252 | 9.6 | 5.07 | – | 481 | 141 | 340 | 4,693 | 3,026 | 1,885 | 1,635 | 15.4 | 1.15 |
| 12/29/18 | 2,266 | 331 | 226 | 10.0 | 4.62 | – | 441 | 140 | 301 | 3,856 | 2,518 | 1,611 | 1,317 | 17.2 | 1.22 |
| 12/30/17 | 1,858 | 288 | 123 | 6.6 | 2.54 | – | 318 | 82 | 236 | 2,930 | 1,866 | 1,086 | 1,045 | 11.8 | 1.04 |
| 12/31/16 | 1,681 | 238 | 155 | 9.2 | 3.23 | – | 317 | 55 | 262 | 2,712 | 1,858 | 1,181 | 837 | 18.5 | 1.41 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CIK 1100682 · EIN 06-1397316
PRINCIPAL OFFICE:
251 Ballardvale St, Wilmington, MA 01887
Tel.: 781-222-6000
INCORPORATED:
–
INDUSTRY (SEC SIC CODE):
8731 · Services-Commercial Physical & Biological Research
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/27/25, filed 18 February 2026
FORMER NAMES:
CHARLES RIVER LABORATORIES INTERNATIONAL INC; CHARLES RIVER LABORATORIES HOLDINGS INC
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/18/26) · 10-K FY2024 (filed 2/19/25) · 10-K FY2023 (filed 2/14/24) · 10-K FY2022 (filed 2/22/23) · 10-K FY2021 (filed 2/16/22) · 10-K FY2020 (filed 2/17/21) · 10-K FY2019 (filed 2/11/20) · 10-K FY2018 (filed 2/13/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.